Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 24.1% in June

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 7,200 shares, an increase of 24.1% from the May 31st total of 5,800 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 26,300 shares, the short-interest ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BRNS. William Blair reissued an “outperform” rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. Barclays dropped their price target on Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a research note on Thursday, June 13th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Barinthus Biotherapeutics in a report on Friday, June 7th.

Barinthus Biotherapeutics Stock Performance

Shares of NASDAQ BRNS traded up $0.03 during mid-day trading on Monday, hitting $1.43. The stock had a trading volume of 43,784 shares, compared to its average volume of 21,027. The company has a 50 day moving average of $2.05 and a two-hundred day moving average of $2.61. Barinthus Biotherapeutics has a twelve month low of $1.21 and a twelve month high of $5.10. The firm has a market cap of $55.81 million, a PE ratio of -0.77 and a beta of -0.52.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.24. Equities research analysts predict that Barinthus Biotherapeutics will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. BlueCrest Capital Management Ltd purchased a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 542,673 shares of the company’s stock, valued at approximately $1,292,000. BlueCrest Capital Management Ltd owned 1.39% of Barinthus Biotherapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.